Ficerafusp Alfa + Pembrolizumab for Head and Neck Cancer (FORTIFI-HN01 Trial)
Trial Summary
Pembrolizumab, used in treating head and neck cancer, generally has a manageable safety profile, with common side effects like diarrhea, thyroid issues, and skin rash, and rare severe lung inflammation. However, specific safety data for Ficerafusp Alfa in combination with Pembrolizumab is not provided in the available research.
124610Research shows that pembrolizumab, one of the drugs in the combination, is effective in treating head and neck cancer, especially in patients with high levels of PD-L1, a protein that helps cancer cells hide from the immune system.
135910Ficerafusp Alfa combined with Pembrolizumab is unique because it potentially offers a novel approach by combining two different mechanisms: Ficerafusp Alfa's specific action (details not provided) with Pembrolizumab's ability to block PD-1, a protein that helps cancer cells evade the immune system. This combination could enhance the immune system's ability to fight head and neck cancer compared to using Pembrolizumab alone.
157810The trial protocol does not specify if you need to stop taking your current medications. However, if you are on medications like corticosteroids or immunosuppressive drugs, you may need to stop them 7 days before starting the trial treatment.
Eligibility Criteria
This trial is for adults with PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) who haven't been treated before. Participants must meet certain health standards but specific inclusion and exclusion criteria are not provided here.Inclusion Criteria
Exclusion Criteria